Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

    Press/Media: OtherAcademic

    Period19-Aug-2022

    Media coverage

    1

    Media coverage

    • TitlePotential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION
      Degree of recognitionInternational
      Media name/outletBio Med Central
      Media typeOther
      Date19/08/2022
      Producer/AuthorJan Kloka1†, Benjamin Friedrichson1†, Stephanie Dauth2,3, Ann Christina Foldenauer2, Anita Bulczak‐Schadendorf2, Maria J. G. T. Vehreschild4, Francisco Maio Matos5, Antoni Riera‐Mestre6,7,8, Antoinette D. I. van Asselt9, Edoardo De Robertis10, Vilma Traskaite Juskeviciene11, Patrick Meybohm12, Dana Tomescu13, Karine Lacombe14, Coen D. A. Stehouwer15,16, Kai Zacharowski1* and on behalf of the IXION Collaboration Group
      URLtrialsjournal.biomedcentral.com/track/pdf/10.1186/s13063-022-06609-x
      PersonsRené van Hulst